Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
dynavax
Overview
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative vaccines, primarily focused on infectious diseases. Operating within the biotechnology and pharmaceutical sectors, Dynavax leverages its proprietary Toll-like receptor (TLR) 9 agonist technology, notably CpG 1018, as an adjuvant to enhance vaccine efficacy. The company's leading product, HEPLISAV-B, a hepatitis B vaccine for adults, has established Dynavax as a significant player in the vaccine market, with ongoing efforts to expand its product portfolio and explore new applications of its TLR9 agonist technology.
dynavax's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 6 |
Consulting | 1 |
Service | 0 |
Design | 0 |
Education | 0 |
Dynavax's department distribution showcases a commercially-focused biopharmaceutical company with a strong emphasis on sales and marketing to support its marketed product, HEPLISAV-B. The high number of employees in the Sales department (71) underscores the company's active efforts to drive adoption and market penetration of their key product. A significant allocation of resources to Medical Affairs (16) and Research (12) reflects Dynavax's commitment to ongoing clinical development, post-market surveillance, and the potential discovery of new vaccine candidates or applications for its core technology. The substantial number of employees categorized under 'Other Department' (73) likely encompasses manufacturing, quality control, and related operational roles essential for vaccine production, indicating a significant investment in internal manufacturing capabilities. The relatively lean structure in Administrative (6), HR (6), and Finance (11) suggests a streamlined corporate overhead, enabling efficient allocation of resources to revenue-generating and R&D activities. The absence of dedicated Customer Service and Design departments may point to outsourcing these functions or integrating them within other departments. Overall, the department breakdown signifies a balanced approach, prioritizing commercial success while maintaining a strong foundation in research and development, aligning well with the dynamics of the biopharmaceutical industry.
dynavax's employees by locations
Employee Count by Country
Total: 258 employees
Dynavax's geographic distribution is heavily concentrated in the United States (239 employees), indicating its primary operational and commercial base. This aligns with the initial market launch and primary sales focus of HEPLISAV-B within the US. The presence of a smaller, but notable, contingent of employees in Germany (14) likely reflects Dynavax's commercial operations for HEPLISAV-B within the European market, where they have regulatory approval and are actively marketing the vaccine. The minimal presence in the United Kingdom, Ireland, Italy, and the Philippines (1-2 employees each) suggests a limited direct presence in these countries, potentially related to ongoing clinical trials, regulatory affairs support, or nascent market exploration activities. The limited global footprint beyond the US and Germany suggests that Dynavax may rely on partnerships, distributors, or regional licensing agreements to access other global markets. This geographic strategy is consistent with a focused commercialization approach, prioritizing key markets with established healthcare infrastructure and reimbursement mechanisms for vaccines.
Want to stay ahead of dynavax's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early